IN.PACT AV Access Trial Meets Primary Safety and Effectiveness Endpoints

Ads

You May Also Like

AnaptysBio Announces First-In-Human Dosing of ANB019

SAN DIEGO, April 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology ...

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, 17 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] ...